Experts advocate three-pronged approach to identifying missing tuberculosis cases

As Ab­b­Vie’s CEO, Rick Gon­za­lez took Hu­mi­ra from a megablock­buster in­to some­thing sin­gu­lar: a pol­i­tics- and com­pe­ti­tion-de­fy­ing prod­uct that be­came the best-sell­ing drug of all

Moon­Lake Im­munother­a­peu­tics says it’s cleared the bar in a Phase II tri­al of its IL-17A and IL-17F in­hibitor in hidradeni­tis sup­pu­ra­ti­va. In its 234-pa­tient MI­RA